• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

人乳腺癌细胞的辐射存活率:基于琼脂的克隆形成试验标准

Radiation survival of human mammary carcinoma cells: criteria for an agar-based clonogenic assay.

作者信息

Besch G J, Tanner M A, Sattler C A, Wolberg W H, Howard S P, Gould M N

出版信息

Int J Radiat Oncol Biol Phys. 1986 Jan;12(1):75-81. doi: 10.1016/0360-3016(86)90418-9.

DOI:10.1016/0360-3016(86)90418-9
PMID:3943995
Abstract

A human in vivo-in vitro model for breast cancer has been developed based on culture methods that were systematically optimized for solid breast carcinomas. A V-79 cell clonal agar-based model was used to define the analysis problem encountered with agar based clonogenic survival assays. Based on this, we established methods for the generation and analysis of the survival of primary and recurrent breast carcinomas following irradiation. Four out of five primary breast carcinomas studied had similar radiation-cell survival curves. The fifth tumor was more radioresistant. Interestingly, a recurrent breast carcinoma arising in a heavily irradiated chest wall was no more radioresistant than our series of unirradiated primary carcinomas. These methods may be useful both for the study of the radiobiology of human neoplasms and for customizing the treatments and prognosis of individual patients.

摘要

基于对实体乳腺癌进行系统优化的培养方法,已开发出一种用于乳腺癌的人体体内 - 体外模型。使用基于V - 79细胞克隆琼脂的模型来界定基于琼脂的克隆形成存活测定所遇到的分析问题。基于此,我们建立了对原发性和复发性乳腺癌放疗后存活情况进行生成和分析的方法。所研究的五例原发性乳腺癌中有四例具有相似的放射细胞存活曲线。第五个肿瘤对放疗更具抗性。有趣的是,在受重度照射的胸壁上出现的复发性乳腺癌并不比我们一系列未受照射的原发性癌更具放疗抗性。这些方法对于人类肿瘤放射生物学的研究以及针对个体患者定制治疗方案和预测预后可能都很有用。

相似文献

1
Radiation survival of human mammary carcinoma cells: criteria for an agar-based clonogenic assay.人乳腺癌细胞的辐射存活率:基于琼脂的克隆形成试验标准
Int J Radiat Oncol Biol Phys. 1986 Jan;12(1):75-81. doi: 10.1016/0360-3016(86)90418-9.
2
Clonogenic cell assay for anchorage-dependent squamous carcinoma cell lines using limiting dilution.使用有限稀释法对贴壁依赖性鳞状癌细胞系进行克隆形成细胞测定。
Int J Cancer. 1989 Jul 15;44(1):131-6. doi: 10.1002/ijc.2910440123.
3
The estimation of self-renewal in the clonogenic cells of human solid tumours: a comparison of secondary plating efficiency and colony size.人实体瘤克隆细胞自我更新能力的评估:二次接种效率与集落大小的比较
Br J Cancer. 1985 Aug;52(2):189-95. doi: 10.1038/bjc.1985.177.
4
In vitro clonogenic growth and metastatic potential of human operable breast cancer.人可手术乳腺癌的体外克隆生长及转移潜能
Cancer Res. 1989 Oct 1;49(19):5288-93.
5
The response of tumour cells to radiation and cytotoxic drugs--a comparison of clonogenic and isotope uptake assays.肿瘤细胞对辐射和细胞毒性药物的反应——克隆形成试验与同位素摄取试验的比较
Br J Cancer. 1984 Nov;50(5):625-31. doi: 10.1038/bjc.1984.229.
6
A radiobiological comparison of human tumor soft-agar clonogenic assays.人类肿瘤软琼脂克隆形成试验的放射生物学比较
Int J Cancer. 1986 Jun 15;37(6):897-903. doi: 10.1002/ijc.2910370616.
7
[Survival of clonogenic cells of Lewis lung carcinoma cells forming colonies in agar cultures in diffusion chambers during gamma-irradiation and exposure to gamma-neutron californium-252 irradiation].[γ射线照射及暴露于γ中子锎-252照射期间,在扩散盒琼脂培养中形成集落的Lewis肺癌细胞克隆形成细胞的存活情况]
Radiobiologiia. 1986 Jul-Aug;26(4):473-6.
8
A critical appraisal of clonogenic survival assays in the evaluation of radiation damage to normal tissues.对克隆形成存活试验在评估正常组织辐射损伤中的批判性评价。
Radiother Oncol. 1984 Jan;1(3):241-6. doi: 10.1016/s0167-8140(84)80006-7.
9
Use of cells cultured from human mammary carcinomas for studies of malignant progression and chemotherapeutic drug sensitivity.
J Lab Clin Med. 1987 Mar;109(3):236-43.
10
Effect of tumor colony definition on ionizing radiation survival curves of melanoma-colony forming cells.肿瘤集落定义对黑色素瘤集落形成细胞电离辐射存活曲线的影响。
Int J Radiat Oncol Biol Phys. 1987 Nov;13(11):1725-33. doi: 10.1016/0360-3016(87)90170-2.